Efficacy Study of Avastin® With Pemetrexed +/- Carboplatin to Treat Elderly Patients With Non-small Cell Lung Cancer

Exclusion Criteria

• •Mixed, non-small cell and small cell tumours or mixed adenosquamous carcinomas with a predominant squamous component
• •History of haemoptysis
• •Evidence of tumour invading major blood vessels on imaging
• •Radiotherapy within 28 days prior to enrolment
• •Patients who are unable to interrupt aspirin or other nonsteroidal anti-inflammatory agents, other than an aspirin dose ≤ 1.3 grams per day, for a 5-day period (8-day period for long-acting agents, such as piroxicam)
• •Current or recent (within 10 days of first dose of bevacizumab) use of full-dose oral or parenteral anticoagulants or thrombolytic agent for therapeutic purposes. Prophylactic use of anticoagulants is allowed
• •Clinically significant (i.e. active) cardiovascular disease for example CVA (≤6 months before enrolment), myocardial infarction (≤6 months before enrolment), unstable angina, CHF NYHA Class ≥II, serious cardiac arrhythmia requiring medication during the study and might interfere with regularity of the study treatment, or not controlled by medication
• •Non-healing wound, active peptic ulcer or bone fracture
• •History of abdominal fistula, gastrointestinal perforation or intra-abdominal abscess within 6 months of enrolment